NicOx (NYSE Euronext Paris: COX), a French pharmaceutical company based in Sophia Antipolis, has announced the purchase of an 11.8% equity stake in the Cambridge,… Read More »French company, NicOx builds capability in developing global ophthalmics business
Bausch & Lomb has announced the acquisition of Ista Pharmaceuticals (NASDAQ: ISTA) for $9.10 per share in cash, equating to a purchase price of approximately… Read More »Bausch & Lomb Inc announces acquisition of Ista Pharmaceuticals for $500M
ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on the development of ocular treatments has announced the closure of a EUR77.8 million private… Read More »ThromboGenics raises EUR77.8M in a private placement
Neuron Systems Inc., Burlington, Massachusetts (an investment of Johnson & Johnson Development Corporation and Domain Associates) and pSivida Corp. (NASDAQ:PSDV; ASX:PVA), Watertown, Massachusetts, have announced… Read More »Neuron Systems Inc (J&J) and pSivida Corp enter evaluation deal for implantable delivery device
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), are expected to submit an Investigational New Drug (IND) application for clinical testing… Read More »Genentech and device maker ForSight VISION 4 Inc. progress on sustained delivery device for Lucentis
A Paris-based company founded by Professor Francine Behar-Cohen has announced the closure of a EUR1.6 million funding round led by French investors InnoBio Fund and… Read More »Paris based biotech company, Eyevensys, raises EUR1.6million
Valeant Pharmaceuticals International Inc. (TSX: VRX; NYSE: VRX), an Ontario-based pharmaceuticals company with an estimated value in excess of $13 billion, has announced their agreement… Read More »Valeant Pharmaceuticals, Inc. announces deal to acquire Eyetech Inc.
Regeneron Pharmaceuticals Inc (REGN, Tarrytown, New York) has announced a non-exclusive license and partial settlement with Genentech (RHHBY.PK, a unit of the Roche group) related… Read More »Regeneron & Genentech (almost) settle their VEGF trap dispute
Life Technologies Corporation, a Carlsbad, California based company, has announced the launch of their bench top “Ion Proton Sequencer”, a pH-based sequencing device designed to… Read More »Life Technologies Corp schedules $1,000 genome before the end of 2012
Valeant Pharmaceuticals International Inc. (TSX: VRX; NYSE: VRX), an Ontario-based pharmaceuticals company with an estimated value in excess of $13 billion, has made public an… Read More »Valeant Pharmaceuticals International makes hostile takeover bid for eye care business, Ista Pharmaceuticals